The urokinase receptor (u‐PAR)—a link between tumor cell dormancy and minimal residual disease in bone marrow?
Open accessThe DOI matches its Crossref record.
Abstract
Minimal residual disease (MRD) is hypothesized to be the major cause of tumor recurrence and metastasis even years and decades after primary cancer diagnosis and curative solid tumor resection. In these patients disseminated tumor cells reflecting MRD can be detected in the bone marrow years after treatment. It is to be assumed that genetic determinants and a complex interplay between the disseminated tumor cells and their microenvironment in the bone marrow are responsible for tumor cell dormancy and the final reactivation towards metastasis. The urokinase receptor (u‐PAR), a critical regulator of invasion, intravasation, and metastasis, is found to be a key player in regulating the shift between single cell tumor dormancy and proliferation. This has mainly been attributed to a regulation by u‐PAR of integrins, and the ability of the latter to propagate signals from fibronectin through the EGF‐receptor, ERK, and p38 signaling. Interestingly, u‐PAR is found in disseminated tumor cells in the bone marrow of solid cancer patients, and is associated with the expansion of these cells and clinical prognosis. Here we summarize and discuss findings on disseminated tumor cells in the bone marrow, MRD and the role of u‐PAR in tumor biology, especially focusing on its specific role in providing a switch between tumor cell proliferation and dormancy. Finally, we discuss the hypothesis that u‐PAR might be an essential molecule in bone marrow disseminated tumor cells for long‐term survival during dormancy, and/or reactivation of their proliferation years after primary treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Does tumour dormancy offer a therapeutic target?
Goss, P. E., & Chambers, A. F. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2933 · Cited by 302
Allgayer, H., Mahapatra, S., Mishra, B., Swain, B., Saha, S., Khanra, S., Kumari, K., Panda, V. K., Malhotra, D., Patil, N. S., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02338-2 · Cited by 127
Self-citationTumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer
Jahanban-Esfahlan, R., Seidi, K., Manjili, M. H., Jahanban-Esfahlan, A., Javaheri, T., & Zare, P. (2019) · Cancers · doi:10.3390/cancers11081207 · Cited by 111
“2, inhibition of one of the components of Fibronectin/uPAR/Integrin/ERK/MLCK signaling axis as well as suppressing PI3K/Akt pathway is enough to prevent/treat metastatic tumor growth, meanwhile promoting dormancy state through favoring the p38 MAPK signaling [65,66].”
BackgroundMetrangolo, V., Ploug, M., & Engelholm, L. H. (2021) · Cancers · doi:10.3390/cancers13215376 · Cited by 44
Alpízar‐Alpízar, W., Nielsen, B. S., Sierra, R., Illemann, M., Ramírez, J. A., Arias, A., Durán, S., Skarstein, A., Ovrebo, K., Lund, L. R., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.24755 · Cited by 36
Metadata
- Authors
- ALLGAYER, H., & AGUIRRE‐GHISO, J. A.
- Venue
- APMIS
- Publisher
- Wiley
- Published
- 2008-07
- Volume
- 116
- Issue
- 7-8
- Pages
- 602-614
- ISSN
- 0903-4641 (ISSN-L)
- 1600-0463
- OpenAlex
- W2060313943
- Cited by
- 50
- References
- 0
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The urokinase receptor (u‐PAR)—a link between tumor cell dormancy and minimal residual disease in bone marrow? https://app.cochat.ai/papers/10.1111/j.1600-0463.2008.00997.x
- The paper
- ALLGAYER, H., & AGUIRRE‐GHISO, J. A. (2008). The urokinase receptor (u‐PAR)—a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS. https://doi.org/10.1111/j.1600-0463.2008.00997.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.